13 results on '"Nattaya Damkham"'
Search Results
2. Identification of Arhgef12 and Prkci as genetic modifiers of retinal dysplasia in the Crb1rd8 mouse model.
- Author
-
Sonia M Weatherly, Gayle B Collin, Jeremy R Charette, Lisa Stone, Nattaya Damkham, Lillian F Hyde, James G Peterson, Wanda Hicks, Gregory W Carter, Jürgen K Naggert, Mark P Krebs, and Patsy M Nishina
- Subjects
Genetics ,QH426-470 - Abstract
Mutations in the apicobasal polarity gene CRB1 lead to diverse retinal diseases, such as Leber congenital amaurosis, cone-rod dystrophy, retinitis pigmentosa (with and without Coats-like vasculopathy), foveal retinoschisis, macular dystrophy, and pigmented paravenous chorioretinal atrophy. Limited correlation between disease phenotypes and CRB1 alleles, and evidence that patients sharing the same alleles often present with different disease features, suggest that genetic modifiers contribute to clinical variation. Similarly, the retinal phenotype of mice bearing the Crb1 retinal degeneration 8 (rd8) allele varies with genetic background. Here, we initiated a sensitized chemical mutagenesis screen in B6.Cg-Crb1rd8/Pjn, a strain with a mild clinical presentation, to identify genetic modifiers that cause a more severe disease phenotype. Two models from this screen, Tvrm266 and Tvrm323, exhibited increased retinal dysplasia. Genetic mapping with high-throughput exome and candidate-gene sequencing identified causative mutations in Arhgef12 and Prkci, respectively. Epistasis analysis of both strains indicated that the increased dysplastic phenotype required homozygosity of the Crb1rd8 allele. Retinal dysplastic lesions in Tvrm266 mice were smaller and caused less photoreceptor degeneration than those in Tvrm323 mice, which developed an early, large diffuse lesion phenotype. At one month of age, Müller glia and microglia mislocalization at dysplastic lesions in both modifier strains was similar to that in B6.Cg-Crb1rd8/Pjn mice but photoreceptor cell mislocalization was more extensive. External limiting membrane disruption was comparable in Tvrm266 and B6.Cg-Crb1rd8/Pjn mice but milder in Tvrm323 mice. Immunohistological analysis of mice at postnatal day 0 indicated a normal distribution of mitotic cells in Tvrm266 and Tvrm323 mice, suggesting normal early development. Aberrant electroretinography responses were observed in both models but functional decline was significant only in Tvrm323 mice. These results identify Arhgef12 and Prkci as modifier genes that differentially shape Crb1-associated retinal disease, which may be relevant to understanding clinical variability and underlying disease mechanisms in humans.
- Published
- 2022
- Full Text
- View/download PDF
3. YAP as a key regulator of adipo-osteogenic differentiation in human MSCs
- Author
-
Chanchao Lorthongpanich, Kanjana Thumanu, Kantpitchar Tangkiettrakul, Nittaya Jiamvoraphong, Chuti Laowtammathron, Nattaya Damkham, Yaowalak U-pratya, and Surapol Issaragrisil
- Subjects
FTIR microspectroscopy ,Dobutamine ,LPA ,MSCs ,Adipo-osteogenic balance ,YAP ,Medicine (General) ,R5-920 ,Biochemistry ,QD415-436 - Abstract
Abstract Background Mesenchymal stem cells (MSCs) are multipotent stem cells that are able to differentiate into several cell types, including cartilage, fat, and bone. As a common progenitor, MSC differentiation has to be tightly regulated to maintain the balance of their differentiation commitment. It has been reported that the decision process of MSCs into fat and bone cells is competing and reciprocal. Several factors have been suggested as critical factors that affect adipo-osteogenic decision, including melatonin and smad4. Yes-associated protein (YAP) is an important effector protein in the Hippo signaling pathway that acts as a transcriptional regulator by activating the transcription of the genes involved in cell proliferation and anti-apoptosis. The non-canonical role of YAP in regulating bone homeostasis by promoting osteogenesis and suppressing adipogenesis was recently demonstrated in a mouse model. However, it is unclear whether YAP is also crucial for modulating human MSC differentiation to fat and bone. Methods The expression level of YAP during MSC differentiation was modulated using pharmaceutical molecule and genetic experiments through gain- and loss-of-function approaches. Results We demonstrated for the first time that YAP has a non-canonical role in regulating the balance of adipo-osteogenic differentiation of human MSCs. The result from synchrotron radiation-based Fourier transform infrared (FTIR) microspectroscopy showed unique metabolic fingerprints generated from YAP-targeted differentiated cells that were clearly distinguished from non-manipulated control. Conclusions These results, thus, identify YAP as an important effector protein that regulates human MSC differentiation to fat and bone and suggests the use of FTIR microspectroscopy as a promising technique in stem cell research.
- Published
- 2019
- Full Text
- View/download PDF
4. YAP-depleted iPSC MUSIi012-A-2 maintained all normal stem cell characteristics
- Author
-
Chanchao Lorthongpanich, Chuti Laowtammathron, Nittaya Jiamvoraphong, Pimonwan Srisook, Pimjai Chingsuwanrote, Phatchanat Klaihmon, Nattaya Damkham, Papussorn Terbto, Supaporn Waeteekul, Yaowalak U-pratya, and Surapol Issaragrisil
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Yes-associated protein (YAP) is an important transcriptional coactivator in the Hippo signaling pathway. Using CRISPR/Cas9 technology, we established a stable YAP-knockdown (YAP-KD) induced pluripotent stem cell (iPSC) from the MUSIi012-A cell line. The YAP-KD iPSC MUSIi012-A-2 maintained the pluripotent phenotype, the ability to differentiate into all three embryonic germ layers, and it maintained the normal karyotype. Keywords: YAP, Hippo signaling pathway, iPSC
- Published
- 2020
- Full Text
- View/download PDF
5. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system
- Author
-
Methichit Wattanapanitch, Nattaya Damkham, Ponthip Potirat, Kongtana Trakarnsanga, Montira Janan, Yaowalak U-pratya, Pakpoom Kheolamai, Nuttha Klincumhom, and Surapol Issaragrisil
- Subjects
Induced pluripotent stem cells ,Thalassemia ,Hematopoietic differentiation ,Genetic correction ,CRISPR/Cas9 ,Medicine (General) ,R5-920 ,Biochemistry ,QD415-436 - Abstract
Abstract Background Thalassemia is the most common genetic disease worldwide; those with severe disease require lifelong blood transfusion and iron chelation therapy. The definitive cure for thalassemia is allogeneic hematopoietic stem cell transplantation, which is limited due to lack of HLA-matched donors and the risk of post-transplant complications. Induced pluripotent stem cell (iPSC) technology offers prospects for autologous cell-based therapy which could avoid the immunological problems. We now report genetic correction of the beta hemoglobin (HBB) gene in iPSCs derived from a patient with a double heterozygote for hemoglobin E and β-thalassemia (HbE/β-thalassemia), the most common thalassemia syndrome in Thailand and Southeast Asia. Methods We used the CRISPR/Cas9 system to target the hemoglobin E mutation from one allele of the HBB gene by homology-directed repair with a single-stranded DNA oligonucleotide template. DNA sequences of the corrected iPSCs were validated by Sanger sequencing. The corrected clones were differentiated into hematopoietic progenitor and erythroid cells to confirm their multilineage differentiation potential and hemoglobin expression. Results The hemoglobin E mutation of HbE/β-thalassemia iPSCs was seamlessly corrected by the CRISPR/Cas9 system. The corrected clones were differentiated into hematopoietic progenitor cells under feeder-free and OP9 coculture systems. These progenitor cells were further expanded in erythroid liquid culture system and developed into erythroid cells that expressed mature HBB gene and HBB protein. Conclusions Our study provides a strategy to correct hemoglobin E mutation in one step and these corrected iPSCs can be differentiated into hematopoietic stem cells to be used for autologous transplantation in patients with HbE/β-thalassemia in the future.
- Published
- 2018
- Full Text
- View/download PDF
6. Generation of a WWTR1 mutation induced pluripotent stem cell line, MUSIi012-A-1, using CRISPR/Cas9
- Author
-
Chanchao Lorthongpanich, Nittaya Jiamvoraphong, Prapasri Supakun, Nattaya Damkham, Papussorn Terbto, Supaporn Waeteekul, Yaowalak U-pratya, Chuti Laowtammathron, and Surapol Issaragrisil
- Subjects
Biology (General) ,QH301-705.5 - Abstract
WWTR1 or TAZ (WWTR1/TAZ) is a transcriptional coactivator that acts as a downstream regulatory target in the Hippo signaling pathway, which plays a pivotal role in regulating cell proliferation and anti-apoptosis. It has been shown in other cell types that WWTR1/TAZ plays a redundant role to its homolog YAP1. Using CRISPR/Cas9 gene editing, we established the WWTR1/TAZ-KO cell line, which features homozygous deletion of WWTR1 gene from human iPSCs. The established WWTR1/YAZ-KO cell line maintained the pluripotent phenotype, the ability to differentiate into all three embryonic germ layers, and normal karyotype.
- Published
- 2019
- Full Text
- View/download PDF
7. Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss
- Author
-
Gayle B. Collin, Navdeep Gogna, Bo Chang, Nattaya Damkham, Jai Pinkney, Lillian F. Hyde, Lisa Stone, Jürgen K. Naggert, Patsy M. Nishina, and Mark P. Krebs
- Subjects
visual photoreceptor cell loss ,mouse genetic models ,retinitis pigmentosa ,Leber congenital amaurosis ,ciliopathies ,Cytology ,QH573-671 - Abstract
Inherited retinal degeneration (RD) leads to the impairment or loss of vision in millions of individuals worldwide, most frequently due to the loss of photoreceptor (PR) cells. Animal models, particularly the laboratory mouse, have been used to understand the pathogenic mechanisms that underlie PR cell loss and to explore therapies that may prevent, delay, or reverse RD. Here, we reviewed entries in the Mouse Genome Informatics and PubMed databases to compile a comprehensive list of monogenic mouse models in which PR cell loss is demonstrated. The progression of PR cell loss with postnatal age was documented in mutant alleles of genes grouped by biological function. As anticipated, a wide range in the onset and rate of cell loss was observed among the reported models. The analysis underscored relationships between RD genes and ciliary function, transcription-coupled DNA damage repair, and cellular chloride homeostasis. Comparing the mouse gene list to human RD genes identified in the RetNet database revealed that mouse models are available for 40% of the known human diseases, suggesting opportunities for future research. This work may provide insight into the molecular players and pathways through which PR degenerative disease occurs and may be useful for planning translational studies.
- Published
- 2020
- Full Text
- View/download PDF
8. Role of YAP as a Mechanosensing Molecule in Stem Cells and Stem Cell-Derived Hematopoietic Cells
- Author
-
Nattaya Damkham, Surapol Issaragrisil, and Chanchao Lorthongpanich
- Subjects
Inorganic Chemistry ,Organic Chemistry ,General Medicine ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy ,Catalysis ,Computer Science Applications - Abstract
Yes-associated protein (YAP) and WW domain-containing transcription regulator protein 1 (WWTR1, also known as TAZ) are transcriptional coactivators in the Hippo signaling pathway. Both are well-known regulators of cell proliferation and organ size control, and they have significant roles in promoting cell proliferation and differentiation. The roles of YAP and TAZ in stem cell pluripotency and differentiation have been extensively studied. However, the upstream mediators of YAP and TAZ are not well understood. Recently, a novel role of YAP in mechanosensing and mechanotransduction has been reported. The present review updates information on the regulation of YAP by mechanical cues such as extracellular matrix stiffness, fluid shear stress, and actin cytoskeleton tension in stem cell behaviors and differentiation. The review explores mesenchymal stem cell fate decisions, pluripotent stem cells (PSCs), self-renewal, pluripotency, and differentiation to blood products. Understanding how cells sense their microenvironment or niche and mimic those microenvironments in vitro could improve the efficiency of producing stem cell products and the efficacy of the products.
- Published
- 2022
9. Identification of Arhgef12 and Prkci as Genetic Modifiers of Retinal Dysplasia in the Crb1rd8 Mouse Model
- Author
-
Jürgen K. Naggert, Nattaya Damkham, James G. Peterson, Sonia M. Weatherly, Mark P. Krebs, Gayle B. Collin, Lillian F. Hyde, Jeremy R. Charette, Wanda L. Hicks, Gregory W. Carter, Lisa Stone, and Patsy M. Nishina
- Subjects
Retinal degeneration ,Pathology ,medicine.medical_specialty ,CRB1 ,medicine.diagnostic_test ,Dystrophy ,Retinal ,Macular dystrophy ,Biology ,medicine.disease ,chemistry.chemical_compound ,chemistry ,Retinitis pigmentosa ,medicine ,Retinal dysplasia ,Electroretinography - Abstract
Mutations in the apicobasal polarity gene CRB1 lead to diverse retinal diseases, such as Leber congenital amaurosis, cone-rod dystrophy, retinitis pigmentosa (with and without Coats-like vasculopathy), foveal retinoschisis, macular dystrophy, and pigmented paravenous chorioretinal atrophy. Limited correlation between disease phenotypes and CRB1 alleles, and evidence that patients sharing the same alleles often present with different disease features, suggest that genetic modifiers contribute to clinical variation. Similarly, the retinal phenotype of mice bearing the Crb1 retinal degeneration 8 (rd8) allele varies with genetic background. Here, we initiated a sensitized chemical mutagenesis screen in B6.Cg-Crb1rd8/Pjn, a strain with a mild clinical presentation, to identify genetic modifiers that cause a more severe disease phenotype. Two models from this screen, Tvrm266 and Tvrm323, exhibited increased retinal dysplasia. Genetic mapping with high-throughput exome and candidate-gene sequencing identified causative mutations in Arhgef12 and Prkci, respectively. Epistasis analysis of both strains indicated that the increased dysplastic phenotype required homozygosity of the Crb1rd8 allele. Retinal dysplastic lesions in Tvrm266 mice were smaller and caused less photoreceptor degeneration than those in Tvrm323 mice, which developed an early, large diffuse lesion phenotype. In both models at one month of age, Müller glia and microglia mislocalization at dysplastic lesions was similar to that in B6.Cg-Crb1rd8/Pjn mice, while photoreceptor cell mislocalization was more extensive. External limiting membrane disruption was comparable in Tvrm266 and B6.Cg- Crb1rd8/Pjn mice but milder in Tvrm323 mice. Immunohistological analysis of mice at postnatal day 0 indicated a normal distribution of mitotic cells in Tvrm266 and Tvrm323 mice, suggesting normal early development. Aberrant electroretinography responses were observed in both models but functional decline was significant only in Tvrm323 mice. These results identify Arhgef12 and Prkci as modifier genes that differentially shape Crb1-associated retinal disease, which may be relevant to understanding clinical variability and underlying disease mechanisms.
- Published
- 2021
- Full Text
- View/download PDF
10. YAP as a key regulator of adipo-osteogenic differentiation in human MSCs
- Author
-
Chuti Laowtammathron, Nattaya Damkham, Nittaya Jiamvoraphong, Chanchao Lorthongpanich, Yaowalak U-Pratya, Kanjana Thumanu, Kantpitchar Tangkiettrakul, and Surapol Issaragrisil
- Subjects
Cell type ,Cellular differentiation ,Hippo pathway ,Medicine (miscellaneous) ,Cell Cycle Proteins ,MSCs ,Biology ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Immunophenotyping ,Umbilical Cord ,lcsh:Biochemistry ,Cell Movement ,Osteogenesis ,Dobutamine ,Adipo-osteogenic balance ,Bone cell ,Spectroscopy, Fourier Transform Infrared ,Adipocytes ,Humans ,lcsh:QD415-436 ,FTIR microspectroscopy ,Cell Proliferation ,Hippo signaling pathway ,lcsh:R5-920 ,Principal Component Analysis ,Adipogenesis ,Osteoblasts ,Research ,Mesenchymal stem cell ,Cell Differentiation ,Mesenchymal Stem Cells ,Cell Biology ,Cell biology ,LPA ,Multipotent Stem Cell ,Molecular Medicine ,YAP ,Stem cell ,Lysophospholipids ,lcsh:Medicine (General) ,Transcription Factors - Abstract
Background Mesenchymal stem cells (MSCs) are multipotent stem cells that are able to differentiate into several cell types, including cartilage, fat, and bone. As a common progenitor, MSC differentiation has to be tightly regulated to maintain the balance of their differentiation commitment. It has been reported that the decision process of MSCs into fat and bone cells is competing and reciprocal. Several factors have been suggested as critical factors that affect adipo-osteogenic decision, including melatonin and smad4. Yes-associated protein (YAP) is an important effector protein in the Hippo signaling pathway that acts as a transcriptional regulator by activating the transcription of the genes involved in cell proliferation and anti-apoptosis. The non-canonical role of YAP in regulating bone homeostasis by promoting osteogenesis and suppressing adipogenesis was recently demonstrated in a mouse model. However, it is unclear whether YAP is also crucial for modulating human MSC differentiation to fat and bone. Methods The expression level of YAP during MSC differentiation was modulated using pharmaceutical molecule and genetic experiments through gain- and loss-of-function approaches. Results We demonstrated for the first time that YAP has a non-canonical role in regulating the balance of adipo-osteogenic differentiation of human MSCs. The result from synchrotron radiation-based Fourier transform infrared (FTIR) microspectroscopy showed unique metabolic fingerprints generated from YAP-targeted differentiated cells that were clearly distinguished from non-manipulated control. Conclusions These results, thus, identify YAP as an important effector protein that regulates human MSC differentiation to fat and bone and suggests the use of FTIR microspectroscopy as a promising technique in stem cell research.
- Published
- 2019
11. MOESM3 of YAP as a key regulator of adipo-osteogenic differentiation in human MSCs
- Author
-
Chanchao Lorthongpanich, Kanjana Thumanu, Kantpitchar Tangkiettrakul, Nittaya Jiamvoraphong, Chuti Laowtammathron, Nattaya Damkham, Yaowalak U-Pratya, and Surapol Issaragrisil
- Abstract
Additional file 3: Figure S3. FTIR spectral signatures of MSCs treated with LPA or DH during differentiation towards osteoblasts or adipocytes. Second derivative spectral (A, E), two-dimensional PCA score plot of all recorded FTIR spectra of DH, LPA, and control cells (B, F). Score loading of PC1 (C, G) and PC2 (D, H) to identify the variable corresponding to wavelength number. Blue dots represent non-treated control, green triangles represent DH, and red squares represent LPA treated cells. Eclipses depicted in the plot define the confidence level with which 95% of the data are allocated. (PPTX 450 kb)
- Published
- 2019
- Full Text
- View/download PDF
12. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system
- Author
-
Nuttha Klincumhom, Methichit Wattanapanitch, Montira Janan, Yaowalak U-Pratya, Ponthip Potirat, Surapol Issaragrisil, Kongtana Trakarnsanga, Nattaya Damkham, and Pakpoom Kheolamai
- Subjects
0301 basic medicine ,Male ,medicine.medical_treatment ,Thalassemia ,Induced Pluripotent Stem Cells ,Medicine (miscellaneous) ,Hematopoietic stem cell transplantation ,Biology ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,lcsh:Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,medicine ,Autologous transplantation ,Humans ,lcsh:QD415-436 ,Progenitor cell ,Induced pluripotent stem cell ,Autografts ,CRISPR/Cas9 ,Hematopoietic differentiation ,Gene Editing ,lcsh:R5-920 ,Research ,Hemoglobin E ,beta-Thalassemia ,Cell Biology ,medicine.disease ,Haematopoiesis ,030104 developmental biology ,030220 oncology & carcinogenesis ,Genetic correction ,Mutation ,Cancer research ,Molecular Medicine ,Female ,Stem cell ,CRISPR-Cas Systems ,lcsh:Medicine (General) ,Stem Cell Transplantation - Abstract
Background Thalassemia is the most common genetic disease worldwide; those with severe disease require lifelong blood transfusion and iron chelation therapy. The definitive cure for thalassemia is allogeneic hematopoietic stem cell transplantation, which is limited due to lack of HLA-matched donors and the risk of post-transplant complications. Induced pluripotent stem cell (iPSC) technology offers prospects for autologous cell-based therapy which could avoid the immunological problems. We now report genetic correction of the beta hemoglobin (HBB) gene in iPSCs derived from a patient with a double heterozygote for hemoglobin E and β-thalassemia (HbE/β-thalassemia), the most common thalassemia syndrome in Thailand and Southeast Asia. Methods We used the CRISPR/Cas9 system to target the hemoglobin E mutation from one allele of the HBB gene by homology-directed repair with a single-stranded DNA oligonucleotide template. DNA sequences of the corrected iPSCs were validated by Sanger sequencing. The corrected clones were differentiated into hematopoietic progenitor and erythroid cells to confirm their multilineage differentiation potential and hemoglobin expression. Results The hemoglobin E mutation of HbE/β-thalassemia iPSCs was seamlessly corrected by the CRISPR/Cas9 system. The corrected clones were differentiated into hematopoietic progenitor cells under feeder-free and OP9 coculture systems. These progenitor cells were further expanded in erythroid liquid culture system and developed into erythroid cells that expressed mature HBB gene and HBB protein. Conclusions Our study provides a strategy to correct hemoglobin E mutation in one step and these corrected iPSCs can be differentiated into hematopoietic stem cells to be used for autologous transplantation in patients with HbE/β-thalassemia in the future. Electronic supplementary material The online version of this article (10.1186/s13287-018-0779-3) contains supplementary material, which is available to authorized users.
- Published
- 2018
13. Additional file 1: Tables S1â S6. of One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system
- Author
-
Methichit Wattanapanitch, Nattaya Damkham, Ponthip Potirat, Kongtana Trakarnsanga, Montira Janan, Yaowalak U-Pratya, Pakpoom Kheolamai, Nuttha Klincumhom, and Surapol Issaragrisil
- Abstract
Presenting primer and oligo sequences. (DOCX 20 kb)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.